Dr. Samer Zaid Kaylani
Claim this profileTexas Tech University Health Sciences Center-Amarillo
Area of expertise
Cancer
Samer Zaid Kaylani has run 4 trials for Cancer. Some of their research focus areas include:
Leukemia
Samer Zaid Kaylani has run 3 trials for Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Texas Tech University Health Sciences Center-Amarillo
Clinical Trials Samer Zaid Kaylani is currently running
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting
1 award
Phase 2
12 criteria
Health Information Collection
for Childhood Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Recruiting
1 award
N/A
10 criteria
More about Samer Zaid Kaylani
Clinical Trial Related
19 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Samer Zaid Kaylani has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Cytology Specimen Collection Procedure
- Radiation Therapy
- Dexamethasone
Breakdown of trials Samer Zaid Kaylani has run
Cancer
Leukemia
Rhabdomyosarcoma
Burkitt Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Samer Zaid Kaylani specialize in?
Samer Zaid Kaylani focuses on Cancer and Leukemia. In particular, much of their work with Cancer has involved FOXO1 fusion negative patients, or patients who are FOXO1 fusion positive.
Is Samer Zaid Kaylani currently recruiting for clinical trials?
Yes, Samer Zaid Kaylani is currently recruiting for 2 clinical trials in Amarillo Texas. If you're interested in participating, you should apply.
Are there any treatments that Samer Zaid Kaylani has studied deeply?
Yes, Samer Zaid Kaylani has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Samer Zaid Kaylani?
Apply for one of the trials that Samer Zaid Kaylani is conducting.
What is the office address of Samer Zaid Kaylani?
The office of Samer Zaid Kaylani is located at: Texas Tech University Health Sciences Center-Amarillo, Amarillo, Texas 79106 United States. This is the address for their practice at the Texas Tech University Health Sciences Center-Amarillo.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.